Eli Lilly and Company

Grove Biopharma is a biotechnology company specializing in materials science solutions for peptide therapeutics. It focuses on discovering and developing novel 'protein-like polymers' to address significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatment approaches. This enables patients to access effective and safe treatments for neurological, inflammatory, and oncological conditions.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Chimagen Biosciences specializes in developing a novel class of multi-functional monoclonal antibodies for cancer therapy.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Founded in 2021, Arda Therapeutics is a biotechnology company based in the San Francisco Bay Area. It specializes in developing transformative therapeutics to eliminate pathogenic cells that drive chronic diseases and aging.

Amprion is a biotechnology company specializing in the development of diagnostic tests for brain diseases. Founded in 2007, it is headquartered in San Francisco, California. The company focuses on detecting pathological α-synuclein in cerebrospinal fluid to aid clinicians in diagnosing neurodegenerative conditions like Parkinson's and Lewy body dementia.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Ionetix Corporation specializes in the development, manufacturing, and distribution of superconducting cyclotrons designed for point-of-care production of positron emission tomography (PET) radioisotopes. Established in 2010, the company is headquartered in San Francisco, California, with an additional location in Lansing, Michigan. Ionetix offers the ION-12SC system, which produces N-13 ammonia for PET myocardial perfusion imaging. Its compact cyclotron technology provides advantages such as smaller size, lighter weight, lower power requirement, and a reduced price point compared to conventional designs. The company installs, operates, and manages cyclotrons near imaging suites to provide necessary doses of Ammonia N-13.

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies to treat serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Radar Therapeutics is a pioneering company specializing in precision-expressed mRNA-based therapeutics designed to combat pathogenic cells by targeting their unique transcriptional signatures. The company has developed advanced ribonucleic acid sensing technology, which incorporates control elements for creating rationally designed, precise, and programmable therapies. This innovative approach allows for the targeting of previously undruggable therapeutic targets, enabling healthcare professionals to administer treatments that can either eliminate or reprogram specific pathogenic cells effectively. Through its groundbreaking advancements, Radar Therapeutics aims to provide novel solutions for complex diseases, fundamentally changing the landscape of therapeutic development.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Ajax Therapeutics is a New York City-based biotechnology company that applies computational chemistry and structure-based technologies to develop novel small molecules for treating hematologic malignancies.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

Beijing Targeting One Technology Co., Ltd. specializes in the development and production of biomedical instruments and consumables, focusing on in vitro diagnostic reagents for precision medicine, health management, and life science research. Established in 2015 and based in Beijing, the company offers a range of products including sample preparation apparatus, biochip readers, digital PCR supplies, and genetic testing kits. Its digital PCR solutions play a crucial role in medical diagnostics, with applications in transplant rejection monitoring, targeted sequencing, tumor liquid biopsy, and non-invasive prenatal screening. Targeting One aims to enhance gene testing and precision medicine through its innovative technologies and comprehensive offerings.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Synnovation Therapeutics is a precision oncology company that specializes in the development of small molecule therapies aimed at addressing key driver mechanisms in cancer. The company is committed to discovering and advancing therapeutics that enhance the quality of life for cancer patients. By leveraging its expertise in medicinal chemistry, cancer biology, and patient-focused precision medicine, Synnovation Therapeutics cultivates a diverse pipeline of innovative targeted therapies. Its objective is to efficiently progress these agents into clinical trials, ultimately transforming the standard of care in cancer treatment and improving patient outcomes.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

Akura Medical develops next-generation thrombectomy devices designed to simplify clot removal with a single-pass procedure, offering an easy-to-use solution to efficiently remove blood clots. The company also provides a range of surgical, medical, dental, and veterinary instruments to support clinicians in addressing venous thromboembolism and other clot-related conditions across diverse patient populations.

Laverock Therapeutics develops a gene silencing platform for creating programmable, allogeneic cell therapies.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

Pixin Technology is a provider of decision-making products for medical imaging using artificial intelligence.

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations.

Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

DiogenX is a French biotechnology company founded in 2019, focused on developing therapeutic solutions for diabetic patients. It specializes in pancreatic beta-cell modulators for treating Type 1 and Type 2 diabetes by regenerating insulin-producing cells.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Switch Therapeutics is a biotechnology company founded in 2020 and based in San Francisco, California. The company focuses on revolutionizing RNA interference (RNAi) therapies by developing biomarker-gated genetic medicines. These innovative therapies utilize nucleic acid nanotechnology and RNAi science to target a variety of diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. Switch Therapeutics aims to provide healthcare providers with RNA molecules and therapies that can be activated selectively in specific cells, enhancing the precision of treatments for central nervous system diseases.

IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in genetically programming mRNA to deliver innovative therapies aimed at enhancing patient outcomes. Founded in 2017, the company develops mRNA programming technology that allows for precise control over the location, timing, and intensity of therapeutic protein expression within the body. By employing mRNA-encoded logic circuits, Strand Therapeutics can achieve cell-type specific expression by detecting unique miRNA signatures and modulating protein dosage in response to externally administered small molecules. The company focuses on creating gene therapies powered by synthetic biology, including immunotherapies designed to enable cells to produce target cancer-killing proteins, thereby strengthening the body's immune response against cancer.

Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Akouos is a biotechnology company focused on precision genetic medicine to restore and preserve hearing. Based in Boston, it develops gene therapies using a proprietary adeno-associated viral vector platform and delivery approaches to treat sensorineural hearing loss in genetically defined populations. The company's lead program, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos pursues research and development across gene-based interventions aimed at improving auditory function and long-term sensory outcomes. It has collaborations with academic and industry partners, including Massachusetts Eye and Ear and Lonza, to advance discovery and manufacturing capabilities. Founded in 2016, Akouos addresses unmet clinical needs in auditory health by seeking to restore physiologic hearing through targeted genetic therapies.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

Iterative Scopes, Inc. is a Boston-based company established in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and life sciences professionals within the colorectal cancer and inflammatory bowel disease sectors. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical areas of healthcare.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for oncology, metabolic diseases, and autoimmune diseases. The company utilizes its proprietary CARD (Computer Accelerated Rational Discovery) platform, which integrates structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development to create clinically differentiated therapeutics. With a world-class scientific team, Regor Therapeutics is committed to efficiently producing both best-in-class and first-in-class molecules, advancing its mission to improve patient outcomes through novel therapeutic solutions.

Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

OriGynMED provides deep professional resources for the invested companies through its global ecosystem to help the business development of the companies. It is a technology-based medical company.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

ForQaly is a medical device company specializing in the development of minimally invasive ventricular assist devices aimed at treating heart failure. The company focuses on creating therapeutic solutions that enhance circulation for patients, ensuring affordability and ease of use for healthcare providers. By prioritizing small trauma and large auxiliary flow in its designs, ForQaly's products are intended to offer effective and accessible care for individuals suffering from heart-related conditions, ultimately improving patient outcomes and quality of life.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients with neurodegenerative diseases. The company's proprietary platform employs human genetics and patient-derived neuronal cells to identify and validate novel disease pathways related to lysosomal dysfunction or aberrant immune system activation, aiming to translate these findings into clinically effective treatments.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Ionova Life Science Co., Ltd. is a biotechnology company founded in 2016 and based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. The company specializes in the discovery and development of novel medicines for cancer treatment, focusing on oncology, including immune-oncology and targeted delivery approaches. Ionova is dedicated to creating innovative tumor-targeted drugs and immunomodulatory therapies for cancer and related diseases, employing its proprietary discovery platform to advance its research and product development initiatives.

MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.

Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Iterative Scopes, Inc. is a Boston-based company established in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and life sciences professionals within the colorectal cancer and inflammatory bowel disease sectors. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical areas of healthcare.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

Protomer Technologies Inc. is a pre-clinical stage biotechnology company based in Pasadena, California, founded in 2014. The company specializes in the development of therapeutic proteins and peptides through its proprietary platform known as Molecular Engineering of Protein Sensors (MEPS). This innovative platform allows for the creation of proteins that can sense molecular activators in the body and be activated as needed, facilitating variable dosing and targeted delivery. Protomer's research primarily focuses on metabolic diseases, with a notable product being a glucose-responsive insulin designed to help manage rising sugar levels in individuals with diabetes. Through its advanced protein-engineering capabilities, Protomer Technologies aims to enhance treatment options for patients suffering from metabolic conditions.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

MiNA Therapeutics Limited is a clinical-stage biotechnology company based in London, United Kingdom, focused on the design and development of small activating RNA medicines aimed at restoring normal cellular function. Founded in 2008, the company is dedicated to harnessing gene activation mechanisms to create therapeutic solutions for cancer and other severe diseases. Its product pipeline includes MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA paired with Pembrolizumab for advanced solid tumors. Through its innovative approach, MiNA Therapeutics aims to transform the treatment landscape, enabling healthcare professionals to effectively address challenging medical conditions.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Synthekine Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018, Synthekine utilizes advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to enhance the efficacy of cytokines while minimizing their toxic side effects. The company's innovative Synthekine Platform employs surrogate agonists instead of traditional mutant cytokines to create selective immunotherapies. Its product pipeline features candidates such as STK-009, an orthogonal ligand paired with SYNCAR-001, an orthogonal receptor-modified CAR-T therapy targeting CD-19. Additionally, Synthekine is developing STK-012, partial agonists of IL-2, and other novel immunotherapies that integrate cytokine receptors to initiate new signaling pathways without relying on wild-type cytokines.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Duality Biologics is a biopharmaceutical company focused on oncology and autoimmune diseases, developing novel modality drugs that include antibody-drug conjugates and bispecific antibodies. It operates a sizable internal pipeline of ADCs and bispecific candidates, with multiple programs in clinical development and several preclinical assets. The company has built a next-generation ADC platform with broad global intellectual property rights and aims to translate novel modalities into approved therapies. Its pipeline comprises numerous in-house ADC candidates, including seven clinical-stage ADCs and two next-generation bispecific ADCs, with additional preclinical programs, and some assets have received regulatory designations such as Fast Track.

Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company based in Pudong, China, with an additional office in Suzhou. It specializes in developing next-generation immunotherapies aimed at treating cancer. The company boasts a robust pipeline of innovative molecules that target a wide array of challenges in immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical field, Elpiscience is committed to advancing at least one innovative molecule into clinical trials each year, with the goal of improving treatment options for cancer patients globally.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.

Founded in 2008, Nucleix Ltd. specializes in developing non-invasive molecular diagnostic tests for early cancer detection. Its proprietary tests, Bladder EpiCheck and Lung EpiCheck, identify subtle methylation changes in urine and blood samples respectively.